

action

ACCC Welcomes Its Newest Members

St. Luke's University Health Network, Cancer Center

Easton, Pa.

Delegate Rep: Jesse Keiper, BS

Website: slhn.org

Texas Oncology

Austin, Tex.

Delegate Rep: Tammy Sayers

Website: texasoncology.com

Tulane Medical Center

Tulane Cancer Center

New Orleans, La.

Delegate Rep: Laura Godel, PMP

Website: medicine.tulane.edu/centers-institutes/tulane-cancer-center

A Reminder from ACCC's Bylaws Committee

Dec. 1, 2021, is the deadline for submission of any proposed amendments to the ACCC bylaws. Proposed recommendations should be sent to Betsy Spruill at bspruill@accc-cancer.org. The ACCC bylaws are available online at: accc-cancer.org/bylaws.

75 U.S. Research Sites Participate in ASCO-ACCC Initiative

Originally planned as a pilot project involving between 40 to 50 research sites testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity among clinical trial participants, the joint program was expanded in response to broad interest from the oncology community. The invited sites represent a diverse mix of small and large research sites at community- and academic-based oncology programs, which will allow the American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) to draw actionable conclusions about the effectiveness of the tool and training in a variety of research and clinical settings. Each site has been assigned to participate in the site self-assessment tool pilot study, the implicit bias training program pilot study, or both pilot studies.

This work is part of an ASCO-ACCC initiative to establish evidence-based practical strategies and solutions to advance a vision where every patient with cancer has the opportunity to participate in research, focusing initially on patients who are black and/or Hispanic/Latinx. The collaboration launched in July 2020 with a Request for Ideas to the oncology community seeking novel innovations to remedy participation barriers. If the tool and training prove useful across a variety of research sites, ASCO and ACCC plan to explore a longitudinal intervention study to evaluate their effectiveness in diversifying participation of people from all racial and ethnic marginalized populations historically underrepresented in cancer treatment trials.

ACCC Launches Returning to Practice in the COVID-19 Era Series

With national COVID-19 vaccination rates still low and masking and social distancing mandates changing daily, this education series is designed to help cancer care professionals navigate the uncertain environment of caring for patients with cancer and immunocompromised patients during the continued threat of a global pandemic. The project teaches multidisciplinary cancer care teams what to anticipate as they resume pre-pandemic services, specifically for patients with hematologic malignancies, including chronic lymphocytic leukemia, acute myeloid leukemia, and multiple myeloma.

The learning content is intended to meet cancer care professionals where they are and in the limited time they have with learning tools available to access online, listen, or view in mobile audio podcast and video podcast formats. All educational materials were developed under the guidance of the Returning to Practice Task Force, composed of experienced oncologists, oncology pharmacists, and oncology administrators.

Topics in the Returning to Practice Series include:

- Myeloma Care Strategies and COVID-19 (CANCER BUZZ TV)
- Returning to Practice in the COVID-19 Era: Hematology Disease Education (On-Demand Webinar)
- Chronic Lymphocytic Leukemia Patient Education in Transitional Times (Audio Podcast).

Explore the Returning to Practice Series resources online at ACCC's website at: accc-cancer.org/hematologic-malignancies. The education project was funded in part by AbbVie.